ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31

AbbVie Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$282.68−2.74 (-0.96%)

Close on Oct 19, 2026

Market cap: $500.63B
P/E (TTM): 79.9
Dividend yield: 2.35%

AbbVie Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Revenue	61,160	56,334	54,318	58,054	56,197	45,804	33,266	32,753	28,216	25,638	22,859	19,960	18,790	18,380	17,444
Cost of Revenue	18,204	16,904	20,415	17,414	17,446	15,387	7,439	7,718	7,042	5,832	4,500	4,426	4,581	4,508	4,639
Gross Profit	42,956	39,430	33,903	40,640	38,751	30,417	25,827	25,035	21,174	19,806	18,359	15,534	14,209	13,872	12,805
Research & Development	9,096	12,791	7,675	6,510	6,922	6,379	6,407	10,329	5,007	4,385	4,285	3,297	2,855	2,778	2,618
Selling, General & Admin	14,010	14,752	12,872	15,260	12,349	11,299	6,942	7,399	6,295	5,881	6,387	7,724	5,352	4,989	5,894
Advertising Expenses	2,100	2,100	2,200	2,000	2,100	1,800	1,100	1,100	846	764	704	665	626	506	375
Total Costs & Expenses	46,085	47,197	41,561	39,937	38,273	34,441	20,283	26,370	18,671	16,298	15,322	16,549	13,126	12,563	13,824
Operating Income	15,075	9,137	12,757	18,117	17,924	11,363	12,983	6,383	9,545	9,340	7,537	3,411	5,664	5,817	3,620
Interest Expense	2,893	2,808	2,224	2,230	2,423	2,454	1,784	1,348	1,150	1,047	719	429	299	104	–
Interest & Investment Income	266	648	540	186	39	174	275	204	146	82	33	38	21	20	20
Other Non-Operating Income	-5,793	-3,240	-4,677	-2,448	-2,500	-5,614	-3,006	-18	-466	-188	-13	27	1.00	9.00	-2.00
Merger & Restructuring Charges	–	–	–	–	–	–	219	59	86	52	126	16	83	–	–
Pretax Income	6,597	3,716	6,250	13,477	12,989	3,398	8,426	5,197	7,727	7,884	6,645	2,369	5,332	5,725	3,668
Income Tax Expense	2,364	-570	1,377	1,632	1,440	-1,224	544	-490	2,418	1,931	1,501	595	1,204	450	235
Net Income incl. Noncontrolling Interests	4,233	4,286	4,873	11,845	11,549	4,622	7,882	5,687	–	–	–	–	–	–	–
Minority Interest in Earnings	7.00	8.00	10	9.00	7.00	6.00	0	0	–	–	–	–	–	–	–
Net Income	4,226	4,278	4,863	11,836	11,542	4,616	7,882	5,687	5,309	5,953	5,144	1,774	–	–	–
Net Income to Common	4,186	4,238	4,820	11,782	11,468	4,556	7,842	5,657	5,283	5,923	5,118	1,765	4,128	5,275	3,433
EPS (Basic)(per share)	2.37	2.40	2.73	6.65	6.48	2.73	5.30	3.67	3.31	3.65	3.15	1.11	2.58	3.35	2.18
EPS (Diluted)(per share)	2.36	2.39	2.72	6.63	6.45	2.72	5.28	3.66	3.30	3.63	3.13	1.10	2.56	3.35	2.18
Shares Outstanding (Basic, Weighted)(shares)	1,769	1,769	1,768	1,771	1,770	1,667	1,481	1,541	1,596	1,622	1,625	1,595	1,589	1,577	1,577
Shares Outstanding (Diluted, Weighted)(shares)	1,773	1,773	1,773	1,778	1,777	1,673	1,484	1,546	1,603	1,631	1,637	1,610	1,604	1,577	1,577
Dividend per Share(per share)	6.65	6.29	5.99	5.71	5.31	4.84	4.39	3.95	2.63	2.35	2.10	1.75	2.00	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 71.5%
Operating margin: 26.2%
Net margin: 9.8%
Return on equity, FY2025: 15367.3%

Financial strength

Current ratio: 0.81
Debt to equity: -11.93
Debt to assets: 52.4%
Cash to current liabilities: 15.8%

Valuation

P/E ratio: 79.9
Price to sales: 7.78
Price to book: –
Dividend yield: 2.35%